ДРЕССМАН Марлин Мишелл (US),ПОЛИМЕРОПОУЛОС Михаель Х. (US),БАРОЛЬДИ Паоло (US)
申请号：
RU2016133348
公开号：
RU2016133348A
申请日:
2015.01.07
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least 1/2 hour prior to administration, no food at least 1 hour prior to administration, no food at least 1-1/2 hours prior to administration, no food at least 2 hours prior to administration, no food at least 2-1/2 hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.
